| 衛生福利部國家中醫藥研究所 |
2006 |
Cespitulactones A and B, new diterpenoids from Cespitularia taeniata
|
Shen, Ya-Ching; Ho, Ching-Jen; Kuo, Yao-Haur; Lin, Yun-Sheng |
| 國立臺灣大學 |
2010 |
Cespitulins a-D, Novel Diterpenoids from Taiwanese Cespitularia Taeniata
|
林玉麒; 沈雅敬; LIN, YU-CHI; SHEN, YA-CHING |
| 國立成功大學 |
2014-06 |
Cespitulones A and B, Cytotoxic Diterpenoids of a New Structure Class from the Soft Coral Cespitularia taeniata
|
Lin, Yu-Chi; Wang, Shih-Sheng; Chen, Chung-Hsiung; Kuo, Yao-Haur; Shen, Ya-Ching |
| 國立臺灣大學 |
2014 |
Cespitulones A and B, Cytotoxic Diterpenoids of a New Structure Class from the Soft Coral Cespitularia taeniata
|
Lin, Yu-Chi; Wang, Shih-Sheng; Chen, Chung-Hsiung; Kuo, Yao-Haur; Shen, Ya-Ching; 陳春雄; 沈雅敬 |
| 國立東華大學 |
2005 |
Cessation of chronic low-dosage L-NAME treatment may improve endurance performance in trained rats
|
Lin, Chia-Chih; Li, Jia-Yi; Su, Yi-Ting; Hsieh, Sandy S |
| 臺大學術典藏 |
2021-10-15T08:26:47Z |
Cessation of epithelial Bmp signaling switches the differentiation of crown epithelia to the root lineage in a β-catenin-dependent manner
|
Yang Z.; Hai B.; Qin L.; Ti X.; Shangguan L.; Zhao Y.; Wiggins L.; Liu Y.; Feng J.Q.; JULIA YU-FONG CHANG; Wang F.; Liu F. |
| 中山醫學大學 |
2021 |
Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation
|
Lai, CY; Yang, SS; Lee, SW; Tsai, HJ; Lee, TY |
| 臺北醫學大學 |
2008-02 |
Cetia® / 暢寧®錠
|
藥劑部 |
| 臺北醫學大學 |
2010-02 |
Cetirizine® / 勝克敏®內服水劑
|
藥劑部 |
| 高雄醫學大學 |
2006 |
CETP基因多型性和台灣第2型糖尿病患者冠心症之關聯性
|
謝明家;辛世杰;蕭政岳;田凱仁;許世傑;辛錫璋 |
| 東海大學 |
2009 |
Cetrarioid lichen genera and species in NE China
|
Lai, M.-J., Chen, X.-L., Qian, Z.-G., Xu, L., Anti, T. |
| 臺大學術典藏 |
2021-09-09T02:26:28Z |
Cette belle viande: Cézanne's bathers of the Impressionist years, 1872-1880
|
CHIAO-MEI LIU |
| 臺大學術典藏 |
2020-03-05T06:28:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Jau-Yu Liau;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; JAU-YU LIAU; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 國立臺灣大學 |
2015 |
Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations
|
Liang, Yi-Hsin; Lin, Yu-Lin; Liau, Jau-Yu; Tsai, Jia-Huei; Liang, Jin-Tung; Lin, Been-Ren; Hung, Ji-Shiang; Tseng, Li-Hui; Lin, Liang-In; Chang, Yih-Leong; Cheng, Ann-Lii; Yeh, Kun-Huei; 梁逸歆; 林亮音; 曾麗慧; 張逸良; 林育麟; 鄭安理; 葉坤輝; 蔡佳惠; 洪基翔; 林本仁; 廖肇裕; 梁金銅 |
| 臺大學術典藏 |
2018-09-10T15:21:53Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; YIH-LEONG CHANG |
| 臺大學術典藏 |
2018-09-10T15:23:10Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Jin-Tung Liang |
| 臺大學術典藏 |
2018-09-10T15:23:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
JAU-YU LIAU; Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H. |
| 臺大學術典藏 |
2018-09-10T15:25:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang, Y.-H. and Lin, Y.-L. and Liau, J.-Y. and Tsai, J.-H. and Liang, J.-T. and Lin, B.-R. and Hung, J.-S. and Tseng, L.-H. and Lin, L.-I. and Chang, Y.-L. and Cheng, A.-L. and Yeh, K.-H.; Ji-Shiang Hung |
| 臺大學術典藏 |
2020-02-25T05:15:25Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; JI-SHIANG HUNG; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:23Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Yih-Leong Chang;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-06-16T07:53:31Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Liang-In Lin;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; LIANG-IN LIN; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-03-05T07:31:46Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Jia-Huei Tsai;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Yeh K.-H.; Cheng A.-L.; Chang Y.-L.; Lin L.-I.; Tseng L.-H.; JIA-HUEI TSAI; Liang J.-T.; Lin B.-R.; Hung J.-S. |
| 臺大學術典藏 |
2020-03-06T05:26:12Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; YIH-LEONG CHANG; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-05-03T02:20:55Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Jin-Tung Liang;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Yeh K.-H.; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; JIN-TUNG LIANG; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-05-07T02:46:37Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
YI-HSIN LIANG; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-10T07:58:41Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; LI-HUI TSENG; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:29Z |
Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations
|
Liang Y.-H.;Lin Y.-L.;Liau J.-Y.;Tsai J.-H.;Liang J.-T.;Lin B.-R.;Hung J.-S.;Tseng L.-H.;Lin L.-I.;Chang Y.-L.;Cheng A.-L.;Kun-Huei Yeh; Liang Y.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Tseng L.-H.; Lin L.-I.; Chang Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese: Experiences in Taipei Medical University Hospital
|
戴承正; Cheng-Jeng Tai; Chih-Hsiung Wu; Ching-Shyang Chen; Min-Ter Huang; Jeng-Feng Chiou; Chen-Jei Tai |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese:Experiences in Taipei Medical University Hospital
|
吳志雄; 黃銘德; Tai CJ; Wu CH; Chen CS; Huang MT; Chiou JF; Tai CJ; |
| 臺北醫學大學 |
2006 |
Cetuximab plus chemotherapy as salvage treatment for advanced colorectal cancer in Taiwanese；Experiences in Taipei Medical University Hospital
|
邱仲峰; C; J; Tai; C; H; Wu; C; S; Chen; M; T; Huang; J; F; Chiou; C; J; Tai |
| 國立成功大學 |
2024--JAN |
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)
|
Wang;Hung-Ming;Lou;Pei-Jen;Yang;Muh-Hwa;Chen;Tein-Hua;Lien;Ming-Yu;Lin;Jin-Ching;Chen;Jo-Pai;Lu;Wei-Chen;Lu;Hsueh-Ju;Huang;Tai-Lin;Yen;Chia-Jui;Wu;Shang-Yin;Wang;Hui-Ching;Hsieh;Meng-Che |
| 高雄醫學大學 |
2007 |
Cetuximab合併化學治療於轉移性結直腸癌:表皮生長因子受器表現的角色
|
王照元 |
| 中山醫學大學 |
2021 |
Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway
|
Wu, TK; Ou, YC; Chen, YP; Huang, FM; Pan, YR; Lee, CJ |
| 中山醫學大學 |
2021 |
Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-beta/Smad/miR-181b/TIMP3 Signaling Pathway
|
Yue, CH; Chen, CH; Pan, YR; Chen, YP; Huang, FM; Lee, CJ |
| 中山醫學大學 |
2020 |
Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway
|
Yue, CH; Chen, CH; Lee, WT; Su, TF; Pan, YR; Chen, YP; Huang, FM; Lee, CJ |
| 元智大學 |
Sep-23 |
Cetyltrimethylammonium Bromide Reformed Ceria Nanocomposites of Chemical Mechanical Planarization for Silica Wafer
|
You-Sheng Lin; Kuen-Song Lin; Wei‒Chin Tsai; Ndumiso Vukile Mdlov; Cheng-Yang Tan; U-Ser Jeng |
| 中山醫學大學 |
2020 |
Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling
|
Wu, TK; Chen, CH; Lee, WT; Su, TF; Pan, YR; Huang, FM; Lee, CJ |
| 義守大學 |
2008 |
CEV過程下美式回顧型選擇權的評價
|
童三峰; San-Feng Tong |
| 臺大學術典藏 |
2018-09-10T03:46:05Z |
Cezanne: la serie de Chateau Noir
|
劉巧楣; CHIAO-MEI LIU; 劉巧楣 |
| 國立臺灣大學 |
2001-06 |
Cezanne: la serie de Chateau Noir
|
劉巧楣 |
| 中華大學 |
1998 |
CE認證專案研究-以醫療器材為例
|
許峻獻; HSUEN, HSU CHUN |
| 淡江大學 |
2011-11-05 |
CF-002 Analysis, Synthesis and Design of a One-step Dimethyl Ether Production via a Thermodynamic Approach
|
Chen, H.J.; C.W. Fan |
| 臺大學術典藏 |
2022-06-21T23:24:24Z |
CF-NET: COMPLEMENTARY FUSION NETWORK FOR ROTATION INVARIANT POINT CLOUD COMPLETION
|
Chen, Bo Fan; Yeh, Yang Ming; YI-CHANG LU |
| 中原大學 |
2003-01 |
CF/sub 4//C/sub 2/H/sub 2/電漿聚合披覆非對稱性聚[石風]薄膜應用於滲透蒸發分離程序 CF/sub 4//C/sub 2/H/sub 2/ Plasma Deposition onto Asymmetric Polysulfone Membrane for Pervaporation Separation Process
|
方佩珊;杜振源;李魁然;賴君義 |
| 國立成功大學 |
2000 |
CF2Cl2及CFCl3在Si(111)(7X7)表面之光子及電子引發解離及脫附研究
|
溫清榕 |
| 國立成功大學 |
2004-07-24 |
CF3Br分子吸附在Si(111)-7×7之光電子 及光子激發脫附研究
|
謝育秦; Shai, Yi-Chyn |
| 中原大學 |
2003-08-25 |
CF4 / C2H2電漿披覆於非對稱聚碸膜對滲透蒸發之影響
|
方珮珊; Pei-Shan Fang |
| 大葉大學 |
2007-06-07 |
CF4 plasma pre-treatment catalyst effect on surface morphology and field emission properties of thermal chemical vapor deposited carbon nanotubes films
|
Lee, Shih-Fong;Yeha, Kuo-Hui;Chang, Yung-Ping;Hsu, Po-Kai |
| 國立交通大學 |
2014-12-08T15:37:03Z |
CF4 plasma treatment for fabricating high-performance and reliable solid-phase-crystallized poly-Si TFTs
|
Wang, SD; Lo, WH; Lei, TF |
